Tissue Regenix Group PLC Publication of circular and notice of GM (9069N)
May 26 2020 - 2:01AM
UK Regulatory
TIDMTRX
RNS Number : 9069N
Tissue Regenix Group PLC
26 May 2020
26 May 2020
Tissue Regenix Group plc
("Tissue Regenix", the "Group" or the "Company")
Publication of circular and notice of General Meeting
Tissue Regenix announces that a circular containing further
information on its recent fundraise (the "Circular") was posted to
Shareholders on Friday 22 May. The Circular also contains a notice
of General Meeting (the "General Meeting") and accompanying form of
proxy.
The General Meeting will be held at the offices of Squire Patton
Boggs (UK) LLP, 6 Wellington Place, Leeds at 12 noon on 9 June
2020.
The UK Government passed into law mandatory measures in order to
reduce the transmission of COVID-19. These mandatory measures
prohibit, amongst other things, individuals engaging in
non-essential travel and public gatherings of more than two people,
save where the gathering is essential for work purposes (the "Stay
at Home Measures").
The Company is required to hold the General Meeting in order to
implement the planned fundraise. However the Stay at Home Measures
will significantly restrict our ability to follow a standard
shareholder meeting format. In order to ensure shareholders can
comply with the Stay at Home Measures the Board has concluded that
shareholders should not plan to attend the General Meeting in
person. It is currently intended that the General Meeting will be
held with only the minimum number of shareholders present as
required to form a quorum under the Company's Articles of
Association, and who are essential for the business of the General
Meeting to be conducted.
The results of the votes on the proposed resolutions will be
announced in the normal way as soon as practicable after the
conclusion of the General Meeting.
Having regard to their own safety and that of others,
shareholders are respectfully asked to comply with the Stay at Home
Measures and not make plans to attend the General Meeting. To
ensure the safety of the limited number of people whose attendance
is essential, the Company will not be able to allow other
shareholders to gain access to the General Meeting on the day.
Given the restrictions on travel and as to how the meeting itself
may be conducted, shareholders are strongly encouraged to exercise
their right to vote and to submit a proxy as early as possible.
The Circular, notice of General Meeting and accompanying form of
proxy, are also available on the Company's website,
www.tissueregenix.com, in accordance with AIM Rule 20.
For more information:
Tissue Regenix Group plc Tel: 0330 430 3073 /
Caitlin Pearson, Head of Communications 07920272441
========================================== =====================
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Ben Maddison / Alex
Price
========================================== =====================
FTI Consulting Tel: 0203 727 1000
Simon Conway / Victoria Foster Mitchell
/ Mary Whittow
========================================== =====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The Company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.' and
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specialises in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOGAFMATMTTTMAM
(END) Dow Jones Newswires
May 26, 2020 02:01 ET (06:01 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024